We assessed MES-specific genes that were present in the Pediatric Relevant Molecular Target List to enrich for proteins that are recognized as potential therapeutic targets across childhood cancers.46,60 We showed that the receptor tyrosine kinases (RTKs) AXL, EGFR, PDGFRA, PDGFRB, and EPHA2 were specifically enriched in MES-dominant patient samples, as well as MES neuroblastoma cell lines (Figure 3A). This evidence concerns the gene EPHA2 and childhood malignant neoplasm.